The product described is Brucellosis Vaccine, Live (Strain M5 or Strain M5-90) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions. The active ingredient is live attenuated Brucella melitensis cells prepared from the M5 or M5-90 seed stock, intended solely for further manufacture into veterinary vaccines; the API is not a finished dose form and is not administered directly to animals without formulation, stabilisation, release testing, and national regulatory authorisation. The strain designation functions as the product model identifier, with M5 and M5-90 representing separate attenuated seed options that may differ in passage history, colony morphology, and attenuation marker profile. The API is commonly supplied as a lyophilised cake or powder to be incorporated into one of the listed presentations by a licensed manufacturer.

Because live Brucella cells are temperature-sensitive and subject to viability loss during downstream processing, each dosage form imposes discrete process boundaries. The injectable and solution forms are, in practice, suspensions of whole bacterial cells rather than true solutions; sterilising-grade membrane filtration with a pore size of 0.22 µm is technically incompatible with the whole-cell API and must not be inserted into the formulation stream. Terminal heat sterilisation is likewise outside the operational envelope for a live bacterial vaccine.

Occupational exposure to live Brucella melitensis is a zoonotic risk. Propagation of master and working seed cultures is normally performed in contained fermenters with HEPA-filtered venting and closed transfers. Liquid culture volumes may range from 10 L to 1000 L depending on seed scale, with inactivation and cleaning validation required. Lyophilisation of live vaccine API is performed inside contained equipment or cleanroom isolators to protect operators from aerosol exposure. Facilities typically operate under BSL-3 containment for culture propagation and use sealed transfers for downstream formulation where national biosafety rules require it.

What Distinguishes Strain M5-90 From Strain M5 in Field-Level Brucellosis Control?

Both M5 and M5-90 belong to the live attenuated Brucella melitensis vaccine class and are controlled under the same monograph family, but they are not treated as identical master seed lots. A regulatory dossier must state which strain is used for a given production batch; mixing of M5 and M5-90 seed cultures is not permitted unless expressly authorised in the national licence. Strain identity is confirmed using Brucella-specific PCR and slide agglutination with monospecific antisera, with supplementary differentiation by multilocus variable-number tandem-repeat analysis where the manufacturer’s dossier requires it. The two strains may differ in colony morphology, attenuation stability, and residual serological reactivity; however, published head-to-head field data comparing M5 and M5-90 across all target species and dose forms are limited. Consequently, equivalence between the two strains must be established through national monographs and the manufacturer’s stability and potency data rather than assumed from nomenclature.

Serological interference is a critical difference from rough vaccine strains. M5 and M5-90 retain smooth lipopolysaccharide expression, so vaccinated animals can develop antibodies reactive in Rose Bengal, serum agglutination, complement fixation, and smooth-LPS ELISA tests described in OIE Terrestrial Manual Chapter 3.1.4. This serological profile contrasts with Brucella abortus RB51, a rough mutant with reduced O-antigen expression, which offers a different diagnostic interpretation pathway in cattle programmes. Where a DIVA approach is required, an accompanying diagnostic strategy must be validated for M5 or M5-90; published data for a licensed DIVA companion across every production species are limited.

When a Freeze-Dried Live Bacterial API Is Transferred to Tablets or Capsules

Formulation of the lyophilised API into solid oral presentations places live-cell viability under simultaneous mechanical and thermal stress. Stabiliser matrices containing sucrose or trehalose at 5–10% w/v in the pre-lyophilisation bulk are common for live bacterial vaccines, but the exact composition is dossier-specific. On production-scale lyophilisation equipment with shelf areas of 10–20 m², representative primary drying conditions for bacterial vaccines include chamber pressure 0.10–0.20 mbar and shelf ramp rates 0.5–1.0 °C/min. These are not universal Brucella-specific parameters; the collapse temperature must be determined by freeze-drying microscopy or manometric temperature measurement for the specific formulation. Deviation above the collapse temperature produces visible cake collapse and can reduce viable count in a batch-dependent manner.

Direct compression of live bacterial powder on a rotary tablet press should be evaluated over the intended compaction-force range rather than relying on a universal upper limit. Process validation programmes typically capture viable-count recovery at compression pressures such as 50–200 MPa, because published data for a Brucella M5/M5-90 universal maximum compression force are limited. Capsule filling should be conducted at low relative humidity, commonly ≤ 30% RH, where the powder is hygroscopic; moisture uptake above this level can accelerate viability loss and reduce flow consistency. Granulation and premix blending require low-shear equipment unless viability loss is mapped under high-shear conditions. High-shear granulation with impeller tip speeds above 5 m/s can create local temperature excursions and shear damage; a low-shear tumble blender or fluid-bed granulator with inlet air temperature below 35 °C is often used for live bacterial products, but Brucella-specific validation data are required.

For liquid presentations, the term “solution” is a dosage-form classification rather than a physical description; the product is a whole-cell suspension. Aseptic processing is required for injectable suspensions, and preservatives known to be bactericidal to Brucella at use concentration must not be introduced. Liquid suspensions are cold-chain preparations and are not compatible with terminal sterilisation or sterilising-grade filtration.

Batch release of this veterinary API typically includes identity, viability, purity, safety, residual moisture, and pH. The exact acceptance criteria are set by the national licence and the manufacturer’s approved specification; the table below summarises test classes and relevant technical standards.

Because the API contains viable Brucella, sterility testing of finished injectable product is not a simple absence-of-growth test; the manufacturing organism itself may grow unless neutralised or separated. Validated membrane filtration, centrifugation, or selective neutralisation must be used to distinguish product organisms from extraneous contaminants. This is a known bottleneck in batch release and should be addressed during analytical method validation. Published data for a universal acceptance limit applicable to all dosage forms and both strains are limited; therefore, each filed specification is product-specific and should be obtained from the manufacturer’s regulatory dossier.

Strain-Specific Potency Evaluation in Sheep and Goat Monograph Models

Potency studies for this API are conducted in the target species authorised by the national monograph, most commonly sheep and goats, because the product is derived from Brucella melitensis. A challenge model may measure protection against abortion, mortality, or colonisation of lymph nodes and spleen after virulent Brucella challenge, with acceptance criteria defined by the national pharmacopoeia. Vaccination of pregnant animals with live B. melitensis vaccines is generally contraindicated unless the national programme explicitly authorises it and the product label defines the risk. Post-reconstitution shelf life for injectable suspensions is typically short; a representative package insert may state ≤ 4 hours at 2–8 °C, but the filed label governs.

Differences from other live Brucella vaccines are material to the production species and diagnostic interpretation. Brucella abortus S19 is a smooth strain used mainly in cattle; it is not interchangeable with a B. melitensis-derived small-ruminant vaccine. Brucella abortus RB51 is a rough mutant with reduced O-antigen expression, which changes serological monitoring in cattle; M5 and M5-90 are smooth and therefore retain reactivity with smooth-LPS-based serology. Brucella melitensis Rev.1 is a separate smooth small-ruminant vaccine strain; comparative safety and potency against M5 or M5-90 must not be assumed without data generated under the same challenge conditions. National programme choices among these products depend on host species, diagnostic strategy, and licensed target-animal safety data.

Aseptic downstream handling of this live Brucella API requires controlled environmental conditions. Filling and vial sealing for injectable powders or suspensions should occur in an ISO 14644-1 Class 5 zone with a Grade B background or equivalent national requirement. Lyophilisation cycle data should include comparative pressure measurement with a capacitance manometer and Pirani gauge to identify the end of primary drying; batch-to-batch viability variation is often traced to chamber pressure excursions above 0.2 mbar during primary drying or incomplete secondary drying that leaves local residual moisture above the cake-specific threshold. Compressed gases used for pneumatic conveying, spray drying, or inert blanketing should meet ISO 8573-1 Class 2 for water and oil to avoid contamination and moisture uptake.

Material incompatibilities include bactericidal antimicrobials, high concentrations of organic solvents, extremes of pH outside the formulation-validation range, and hypotonic or hypertonic diluents that produce osmotic shock in whole bacterial cells. Where oral granules or premixes are prepared, the formulation should protect viability during gastric transit; published data for Brucella M5/M5-90 survival in all intended oral matrices are limited, so the manufacturer’s potency study must cover the specific matrix and storage period. Live whole-cell Brucella API cannot be filter-sterilised or terminally heat-sterilised, and any preservative added to a liquid vehicle must be shown not to reduce viable count below the filed release specification.